Written by Julia Rostova
The final frontier of capitalism is officially open for public investment. After years of speculation, the aerospace titan founded by Elon Musk is finally preparing to list its shares on the Nasdaq. According to multiple reports, the initial public offering is scheduled to price on June 11, with trading commencing on June 12 under the ticker SPCX.
This is not merely an IPO; it is a macroeconomic event. The company is targeting a valuation between $1.25 trillion and $1.75 trillion, instantly making it one of the most valuable publicly traded entities on Earth. Institutional capital is already scrambling for allocation, with BlackRock reportedly in discussions to invest up to $10 billion. The sheer magnitude of this offering — which would dwarf every previous IPO in history — is already reshaping capital flows across the aerospace and defense sector.
The impending listing is creating a gravitational pull across the entire space economy. The global space industry is projected to grow from $630 billion to $1.8 trillion by 2035, and the “SpaceX Effect” is driving a massive repricing of publicly traded aerospace equities. Investors are suddenly paying attention to launch providers, satellite operators, and defense technology firms that were largely ignored during the AI mania of 2024-2025. For retail investors, the challenge is separating generational wealth creation from IPO day hype — and positioning in the right names before the June 12 liquidity event reshuffles the entire sector.
Thesis on SpaceX (SPCX) — HOLD (Wait for Post-IPO Consolidation)
The temptation to buy SPCX on opening day will be overwhelming, but history provides a brutal warning. According to Nasdaq research, nearly 64% of IPOs underperform the broader market over their first three years. When a company debuts at a $1.75 trillion valuation, the market is pricing in decades of flawless execution across reusable rockets, Starlink’s satellite internet monopoly, and the nascent orbital AI data center business reportedly being developed with Google.
Retail investors rarely secure shares at the offering price. By the time the stock is available on public exchanges, institutional demand often drives the opening trade 30% to 50% higher. We witnessed this phenomenon with Coinbase and Rivian, both of which suffered severe multiple compression in the months following their highly anticipated debuts. The mega-IPO track record is particularly sobering: Facebook declined 50% from its post-IPO peak within six months, Alibaba fell 35%, and Rivian lost over 80%. While SpaceX’s underlying business — dominated by reusable launch architecture, government contracts, and the Starlink satellite network — is fundamentally superior to these comparisons, investors should wait for the inevitable post-IPO volatility to subside before establishing a long-term position. The smartest trade on June 12 is patience.
Thesis on Rocket Lab (RKLB) — BUY
While the market fixates on the trillion-dollar behemoth, the most compelling asymmetric opportunity in the sector is hiding in plain sight. Rocket Lab just reported an exceptional first quarter, generating $136.7 million in revenue and obliterating Wall Street’s estimate of $132.1 million. More importantly, the company’s backlog has doubled year-over-year to $2.2 billion, reflecting surging demand for both its Electron small-launch vehicle and the upcoming medium-lift Neutron rocket.
The catalysts are stacking up rapidly. Rocket Lab recently secured its largest contract in history with a confidential customer for its Neutron and Electron launch vehicles, solidifying its position as the premier alternative launch provider. The company’s strategic acquisition of Motiv Space Systems further expands its capabilities in space robotics, positioning it for NASA’s Artemis missions and the Pentagon’s Golden Dome missile defense initiative. With second-quarter revenue guidance of $225 million to $240 million — dramatically exceeding the Wall Street consensus of $207.5 million — the underlying business is accelerating at a pace that justifies premium valuation. The stock recently surged 30% to a record high, but as institutional capital rotates into the space sector ahead of June 12, Rocket Lab remains the highest-quality pure-play beneficiary of the SpaceX halo effect.
Thesis on Swarmer (SWMR) — SELL
The rising tide of aerospace enthusiasm has lifted speculative assets to dangerous altitudes. Swarmer, an autonomous drone swarm software company that debuted on the Nasdaq in March, saw its stock surge 340% in its first two trading days. The narrative is intoxicating: artificial intelligence meets defense technology, battle-tested in over 100,000 combat missions in Ukraine, with a subscription-based software model that enables partnerships with drone manufacturers worldwide.
However, the financial reality cannot support the valuation. According to its SEC filings, Swarmer generated a mere $310,000 in revenue last year while posting an $8.5 million net loss. Even if the company successfully executes its $33.1 million contract pipeline over the next two years — with roughly $20 million projected for 2026 — the current market capitalization is completely divorced from fundamental reality. The recent expansion into Japan through a Rakuten partnership is promising but pre-revenue. In an environment where the 30-year Treasury yield is breaching 5.12%, holding a cash-burning, hyper-speculative software stock with negligible revenue is an invitation to capital destruction. Investors sitting on massive IPO gains should aggressively take profits before the SpaceX listing absorbs the sector’s speculative capital.
The commercialization of space is undeniably the next great secular growth theme. But as the trillion-dollar leviathan prepares to enter the public markets, investors must maintain rigorous valuation discipline. Buy the established secondary players with exploding backlogs and proven revenue acceleration, avoid the speculative software dreams trading on narrative alone, and let the IPO dust settle before buying the industry leader. The space economy will reward patient capital — not opening-day gamblers.
────────────────────────────────────────────────────────────
Disclaimer: This article is for informational purposes only and does not constitute investment advice. The opinions expressed are those of the author and do not reflect the views of Equities Orbis or its affiliates. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
